Back to search results

Mobile App Support for Oral Chemotherapy in Leukemia

This study is testing a mobile app called ADAPTS (ADherence Assessments and Personalized Timely Support) to help young people with acute lymphoblastic leukemia (ALL) or lymphoma take their oral chemotherapy, 6-mercaptopurine (6-MP), as prescribed. The app sends personalized messages to help you remember and stay on track with your medication. You might be able to join if you are 14-29 years old, have ALL or lymphoma, are in the maintenance phase of treatment, and are taking 6-MP. The study aims to see if the app is practical and acceptable to users. The current recruitment status is unclear, and the study plans to enroll 60 participants.

Study design
This is a small-scale study with 60 participants. It uses a special design where the app's messages are delivered at different times to see what works best.
What's involved
You would participate in this study for two months. This includes a 28-day period where your medication taking is monitored, followed by 28 days using the ADAPTS app while continuing to monitor your medication.
Compensation
Not stated in the trial record.
Follow-up
Your retention in the study will be tracked for up to 12 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT03932903

Mobile Health Intervention to Support Oral Chemotherapy Adherence in Adolescents and Young Adults With Leukemia

Recruiting
NAAges 14+InterventionalSupportive care
Northwestern University
~60 participants
Updated 2026-06-30 on ClinicalTrials.gov
What's tested:ADAPTS (ADherence Assessments and Personalized Timely Support).

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Technical Difficulties
Measured over 28-day intervention period
+5 more outcomes measured

Conditions

Acute Lymphoblastic Leukemia
Lymphoblastic Lymphoma

Explore related trials

Acute Lymphoblastic LeukemiaLymphoblastic Lymphoma

Where it's being run

1 sites across 1 states
Illinois1

Study leadership

  • Alexandra M Psihogios, Ph.D. · PRINCIPAL_INVESTIGATOR · Northwestern University

Who to contact

Alexandra M Psihogios, Ph.D.
[email protected]
312-503-3577
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Ages 14-29
Diagnosed with acute lymphoblastic leukemia (ALL) or lymphoma
In the maintenance phase, completed at least one cycle and has at least one month of maintenance therapy remaining.
Prescribed 6-mercaptopurine (6MP)
English language proficiency
For AYA \<18, must have informed consent from their caregiver.
Nominated by the AYA as a primary caregiver involved in cancer care (can be a parent, relative, partner, friend)
English language proficiency

Exclusion

Cognitive impairments that would limit ability to complete measures, determined by the medical team

What this trial measures

  • Technical Difficulties28-day intervention period

    Number of technical glitches and errors experienced in implementing the intervention

  • Retention RateUp to 12 months

    Number of AYA (and caregiver) subjects who complete the intervention, out of the total number of subjects enrolled in the study (target of 75% or more)

  • Screening RateUp to 12 months

    Number of AYA patients (and matched caregivers) referred and screened for the study

  • Intervention Engagement28-day intervention period

    Number of 1) viewed and 2) acknowledged micro-randomized text messages

  • Recruitment RateUp to 12 months

    Number of AYA patients (and matched caregivers) enrolled in the study out of those who were eligible and invited to participate (target of 75% or more)

  • Intervention AcceptabilityAt completion of 28-day intervention period

    5-point numerical Likert scale; ranging from 0 (not at all) to 4 (completely) to rate intervention acceptability (including satisfaction, appropriateness, perceived positive effects, potential for future use).